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The spotted fever group (SFG) rickettsioses,
which are transmitted by ticks, have a worldwide
distribution. Japanese spotted fever (JSF) is one
of the newcomers of this group (1); the first clini-
cal cases were reported in 1984 (2). The causative
agent was isolated and named Rickettsia
japonica (3). Because outbreaks were sporadic
and limited, clinical reports concerning JSF,
especially from specialists in dermatology and
physiology and from general practitioners, were
scarce. JSF was first found in Tokushima Prefec-
ture, on the island of Shikoku in southwestern
Japan; Tsutsugamushi disease, an important
rickettsiosis in Japan, was found there soon
afterwards (4). Through October 1996, 31 clinical
cases of JSF and 11 cases of Tsutsugamushi
disease were diagnosed at Mahara Hospital,
Tokushima Prefecture. During the same period,
45 cases of human tick bites were recorded in this
JSF-endemic area in the same hospital. This
article describes JSFs history, clinical characteris-
tics, and differences from Tsutsugamushi disease
and summarizes current information about the
epidemiology, vectors, and causative agent of JSF.
History
In the 1980s, clinicians believed that
Tsutsugamushi disease (scrub typhus) was the
only rickettsial disease in Japan except for
sporadic outbreaks of epidemic typhus in the
1950s. In Tokushima Prefecture, neither disease
has been reported in the last two decades. In May
1984, a 63-year-old woman (the wife of a farmer)
was hospitalized at Mahara Hospital with high
fever and erythematous nonpruritic skin eruptions
over the entire body. Antibiotics (ß-lactam and
aminoglycoside) used for common febrile infections
were not effective, but the patient gradually
became afebrile in 2 weeks without effective
treatment. In May and July 1984, two additional
patients with similar symptoms were treated at
the same hospital. Doxycycline was markedly
effective in these cases. Before the onset of
illness, the patients had collected shoots from
bamboo plantations on the same mountain. In
two of the patients, an eschar was observed.
Tsutsugamushi disease was suspected. However,
results of Weil-Felix tests showed positive OX2
serum agglutinins, and OXK were negative in all
three cases. These results did not indicate
Tsutsugamushi disease, but rather OX2-positive
infections, i.e., SFG rickettsioses (1).
The cases were subsequently confirmed by
complement fixation test with antigens of SFG
rickettsiae (5,6). The name Japanese spotted
fever was proposed for these infections (7) and
has been commonly used since then (8-10).
Oriental spotted fever (11) is a synonym for
JSF. The causative agent was isolated in 1986
(12) and named R. japonica (3).
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Clinical Features
The clinical features of the 31 patients whose
illness was diagnosed as JSF at Mahara Hospital
from 1984 to October 1996 were analyzed. The
disease developed abruptly, with the common
symptoms of headache (25 [80%] of 31 patients),
fever (31 [100%] of patients), and shaking chills
(27 [87%]). Other major objective symptoms of
JSF included skin eruptions (31 [100%]) and tick
bite eschars (28 [90%]). Most patients (28 [90%])
complained of malaise; joint and muscle pain or
numbness of the extremities was rarely men-
tioned. In the acute stage, remittent fever accom-
panied by shaking chills was frequently observed.
In severe cases, high fever (40°C or more) con-
tinued for several days (Figure 1). The maximum
body temperature was 38.5°C to 40.8°C (mean
39.5°C), which was higher than that seen in
patients with Tsutsugamushi disease (38.5°C ~
39.1°C). With abrupt high fever or, a few days
after onset, fever of unknown origin, the charac-
teristic erythemas developed on the extremities
and spread rapidly (in a few hours) to all parts of
the body including palms and soles, without
accompanying pain or itching. These eruptions
were the size of a grain of rice or soybean, and the
margin of each of the spots was unclear (Figure
2). The erythemas became remarkable during the
febrile period and tended to spread more over the
extremities than the trunk. Palmar erythema, a
characteristic finding not seen in Tsutsugamushi
disease, disappeared in the early stage of the
disease. The erythemas became petechial after 3
to 4 days, peaked in a week or 10 days, and dis-
appeared in 2 weeks. However, in severe petechial
cases, the brown pigmentation remained for 2
months or more. Eschar was observed on the
hands, feet, neck, trunk, and shoulders of patients
(Figure 3). This eschar generally remained for 1
to 2 weeks, but in some cases it disappeared in a
few days. Eschars in JSF patients are smaller
than those seen in patients with Tsutsugamushi
disease and may be missed without careful obser-
vation. Regional or generalized lymphadenopathy,
which is observed in almost all cases of
Tsutsugamushi disease, was not remarkable in
JSF patients. Swelling of the liver and spleen was
observed in a few patients. One patient had
cardiomegaly (5), and in another area, a patient
had central nervous system involvement (13).
Figure 1. Fever and clinical course, 62-year-old
woman.
Figure 2. Skin eruptions, hospital day 3.
Laboratory Examinations
The results of laboratory examinations of
JSF patients are almost the same as those of
patients with common SFG rickettsioses. During
clinical examinations at the initial stage of the
disease, urinalyses registered a slight positive
reading for protein and occult blood, which may
lead to a misdiagnosis of urinary infection. In the
acute stage, leukocytosis may also be found with
leukopenia (3,600~12,800), and a left shift in
leukocyte count was observed. Thrombocytopenia
(6.8~35.3) may also be found. In week 1 to 2,
leukocyte counts increased slightly, and lympho-
cyte counts tended to increase. Among bio-
chemical examinations, C-reactive proteins were
strongly positive, and liver functions were slightly
impaired but returned to normal in 2 to 3 weeks.107 Vol. 3, No. 2, AprilJune 1997 Emerging Infectious Diseases
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Serologic Results
Serodiagnosis for JSF is usually performed
by the indirect immunoperoxidase (IP) or immuno-
fluorescence (IF) techniques, with antigens pre-
pared from R. japonica or other SFG rickettsiae.
With the IP test, IgG and IgM antibodies were
detected in the sera beginning on day 9 after the
onset of fever; titers of IgG antibodies were
higher than those of IgM antibodies (14). The IF
test had similar results (15). In the 31 clinically
diagnosed cases of JSF in Tokushima Prefecture
at Mahara Hospital, all patients had significant
changes in serum IP antibody titers to R.
japonica, and 27 (87%) had significant changes in
OX2 agglutinin titers by the Weil-Felix technique
(10,14; F. Mahara, unpub. data).
Treatment
Antibiotics such as penicillins, ß-lactams, or
aminoglycosides, commonly used in the empiric
treatment of febrile disease, were completely inef-
fective, but doxycycline and minocycline were mar-
kedly effective in treating the JSF patients (16).
On the first day of hospitalization in one
patient with severe disease (Figure 1), fever of
more than 40°C with shaking chills persisted
after the antibiotics cefazolin and fosfomycin
were administered. The general condition of the
patient worsened and on the morning of the third
day, generalized edema and confusion developed.
On day 3, the patient was given drip infusion of
doxycycline 300 mg per day, which was dra-
matically effective; the fever decreased to 38°C
during the first drip infusion.
In an in vitro study, minocycline was the most
effective antibiotic against R. japonica, followed
by other tetracycline antibiotics (17,18). In con-
trast, the sensitivity to ß-lactam and penicillin
was lower or negligible, but quinolones were
effective against the JSF agent (18). Three patients
were treated with a new quinolone (tosufloxacin
300 mg per day in three divided doses per os),
which proved effective in two cases (9). Patients
with dehydration received drip infusion of doxy-
cycline or minocycline (200 mg to 300 mg per day
for 3 to 7 days), and after becoming afebrile,
received 200 mg per day 2 divided doses to
prevent relapse. Patients suspected of having
JSF should receive empiric therapy with
minocycline or doxycycline without waiting for
serologic confirmation of illness.
Epidemiology
From 1984 to 1995, 144 cases of JSF were
reported by the National Institutes of Health in
Japan (19; Figure 4). Case reports included only
the number of cases and prefectures where cases
were reported, including Tokushima Prefecture.
According to this information, JSF-endemic
prefectures are located along the coast of south-
western and central Japan in a warm climate
(Figure 5). The landscape is diverse, including
bamboo plantations, crop fields, coastal hills, and
forests (20). Of the 31 JSF patients in Tokushima
Prefecture, nine were male, and 22 were female.
Ages were 4 to 78 years, but most patients (68%)
were 60 to 70 years old. The onset of the disease
was 2 to 8 days after work in the fields. In this
prefecture, farmers work in the forest to gather
bamboo shoots in the spring and chestnuts in the
autumn; cases occurred from April to October
Figure 3. Small and shallow eschar on admission,
which disappeared in a few days.
Figure 4. The number of Japanese spotted fever patients
in Japan (19841995).108 Emerging Infectious Diseases Vol. 3, No. 2, AprilJune 1997
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(6,18; Figure 6). In this area, we can distinguish
seasonal differences in the occurrence of JSF and
Tsutsugamushi disease; whereas JSF occurs
from spring to autumn, Tsutsugamushi disease
occurs in winter (NovemberFebruary). Although
seasonal differences occur in the western parts of
Japan, the prevalent seasons for Tsutsugamushi
disease vary in other parts of Japan (21).
Like other SFG rickettsioses, JSF is
presumed to be transmitted by a tick bite. The
high proportion of patients with tick bite eschars
supports this hypothesis. Thirteen JSF patients
(28.9%) recalled tick bites before the onset of
illness; however, the ticks had been lost, and no
specimens from the patients were available for
further study. From 1984 to October 1996, 45
persons with tick bites were recorded at Mahara
Hospital (Table 1).Identified ticks included three
genera and eight species.
Three genera and six species of ticks have
been reported as positive for R. japonica in JSF-
endemic areas (Table 2). Hemolymph samples
from Dermacentor taiwanensis, Haemaphysalis
flava, Haemaphysalis formosensis, Haemaphysalis
hystricis, Haemaphysalis longicornis, and Ixodes
Figure 5. Geographic distributions of JSF and
Tsutsugamushi disease in Japan.
Figure 6. Seasonal prevalence of Japanese spotted
fever and Tsutsugamushi disease.
Table 1. Cases of human tick bites, Mahara Hospital,
1984–1996
Female Male Nymph Larva Total
Haemaphysalis   1   4   5
 flava
Haemaphysalis   8 1   3 2 14
 longicornis
Amblyomma   4 1 12 17
testdunarium
Ixodes ovatus   1   1
Ixodes nipponensis   4   4
Ixodes persulcatus   2   2
Ixodes tanuki   1   1
Haemaphysalis   1   1
 kitaokai
Totals 20 2 21 2 45
ovatus were positive when tested by the IP tech-
nique using a species-specific monoclonal antibody
against  R. japonica (22). R. japonica was also
detected by  IF in  the  hemolymph of  H. longi-
cornis (23). A polymerase chain reaction (PCR)
technique using species-specific primers detected
R. japonica in  H. hystricis (24),  H. flava, and
I. ovatus (25). The agent has also been detected in
H. longicornis by restriction fragment length poly-
morphism of PCR product (23). Of these, H. flava,
H. longicornis, and I. ovatus commonly feed on
humans in Japan (26). Recent tick surveys in Japan
have identified two serotypes or species of SFG
rickettsial isolates other than R. japonica, which
are of uncertain clinical significance (27,28).
Pathogen
The etiologic agent was first isolated from a
patient (in Kochi Prefecture) in 1986 (12). In
1987, the causative rickettsia was also isolated
from a JSF patient in Tokushima Prefecture (29-
31). The former isolate is the type strain YH109 Vol. 3, No. 2, AprilJune 1997 Emerging Infectious Diseases
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(ATCC VR-1363), later named  R. japonica, a new
SFG rickettsia; the latter strain (Katayama) was
the first isolate from JSF-endemic areas outside
Kochi (3,32). The Katayama strain type and R.
japonica were demonstrated by serologic analysis
using monoclonal antibodies (33). Sero-typing by
use of the reciprocal cross-reactions of mouse
antisera to six human isolates from Toku-shima
and the type strain YH or R. japonica also
indicated that these are the same species (34). In
1988, another strain was isolated from a patient
in Awaji Island, Hyogo Prefecture, which is con-
sidered a new area of JSF-endemic disease (35).
Recently, an isolate from a febrile patient
in Wakayama Prefecture was  also reported as
R. japonica (36). In an electron microscopy
study,   R. japonica were generally recognized as
short rods or pleomorphic coccobacillary forms
less than 2 mm in length and 0.5 mm in diameter
and could be found not only in the cytoplasms but
also in the nuclei of the host cells (37). A
multilayered mesosome-like structure was observed
in the rickettsiae multiplying in a host cell (38).
This unique structure has not been reported in
other species except in Rickettsia prowazekii (39).
After the initial isolation, at least 20 rickettsial
strains have been isolated from JSF patients by
cell culture techniques or nude mouse passage in
Tokushima, Kochi, Hyogo, Chiba, and Wakayama
Prefectures. However, it has not been determined
if their strains differ in virulence.
Ten diseases caused by SFG rickettsiae have
been reported in humans (40): Rocky Mountain
spotted fever, Mediterranean spotted fever,
Siberian tick typhus, African tick bite fever,
Queensland tick typhus, Japanese spotted fever,
Israeli spotted fever, Astrakhan spotted fever,
Flinders Island spotted fever, and rickettsialpox.
The clinical symptoms of JSFa triad of high
fever, skin eruptions, and tick bite escharare
similar to those of typical SFG rickettsioses. With
regard to skin eruptions, eschar, and severity of
the disease, JSF is more akin to Mediterranean
spotted fever and Siberian tick typhus than to
Rocky Mountain spotted fever. Recent tick sur-
veys indicated that the most probable vectors of
JSF are H. flava, H. longicornis, and I. ovatus.
In Japan, the clinical features of JSF are
similar to those of Tsutsugamushi disease; how-
ever, close clinical observation exposes the dif-
ferences between the two diseases. Widespread
outbreaks of Tsutsugamushi disease have been
reported repeatedly in recent years (21). No fatal
cases of JSF have been reported. However, death
rates from other SFG rickettsioses (approximately
2.5% for Mediterranean spotted fever [41] and 3%
to 7% from Rocky Mountain spotted fever [42])
suggest that unless JSF is treated appropriately,
it can pose the same risk. If JSF is suspected,
empiric treatment should begin without delay
during the early stages of disease.
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Table 2. Reported tick species positive for Rickettsia
japonica and their prevalence  in endemic disease areas
No. positive/no. examined
Tick species Tokushima Kochi Kanagawa
Dermacentor 3/5a, 1/1b        -     -
taiwanensis
Haemaphysalis    6/36a     3/10a 1-3/90c
flava
Haemaphysalis       -    10/16a     -
formosensis
Haemaphysalis      +d      5/9a     -
hystricis
Haemaphysalis       -  1/1a, 6/9e,     -
longicornis   5-33/33f
Ixodes ovatus    1/13a        -  1/16c
aHemolymph test by immunoperoxidase stain using R. japonica-
specific monoclonal antibody (22).
bIsolation (28).
cPolymerase chain reaction (PCR) using the primers designed for
amplifying the genomic DNA from only R. japonica (25).
dPCR method same as the above (24). Number was not shown.
eHemolymph test by immunoflurescein stain using R. japonica-
specific monoclonal antibody (23).
fRestriction fragment length polymorphism of PCR product (23).110 Emerging Infectious Diseases Vol. 3, No. 2, AprilJune 1997
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